Cargando…
TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
Adoptive therapy with TCR gene-engineered T cells provides an attractive and feasible treatment option for cancer patients. Further development of TCR gene therapy requires the implementation of T-cell target epitopes that prevent “on-target” reactivity towards healthy tissues and at the same time d...
Autores principales: | Straetemans, Trudy, van Brakel, Mandy, van Steenbergen, Sabine, Broertjes, Marieke, Drexhage, Joost, Hegmans, Joost, Lambrecht, Bart N., Lamers, Cor, Bruggen, Pierre van Der, Coulie, Pierre G., Debets, Reno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287115/ https://www.ncbi.nlm.nih.gov/pubmed/22400038 http://dx.doi.org/10.1155/2012/586314 |
Ejemplares similares
-
Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody
por: Saeed, Mesha, et al.
Publicado: (2016) -
Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4(+) T Lymphocytes
por: Chaux, Pascal, et al.
Publicado: (1999) -
T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope
por: Saeed, Mesha, et al.
Publicado: (2020) -
The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome
por: Schultz, Erwin S., et al.
Publicado: (2002) -
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
por: Kunert, Andre, et al.
Publicado: (2013)